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m] Clinical potential and experience of 
voriconazole 
8. de Pauw. Radboird Unruersity Hospital, Dept. o f  Hernatolcyx 
Nijmqen, Netkrrlands 
Disseminated fungal infections have become a major factor in the 
prognosis of patients with compromised immunity. In spite of toxi- 
city, amphotericin €3 is the antifungal agent of choice for disseminated 
iiiycotes. Flucoiiazole offers no protection against aspergillosis, 
whereas itraconazole, in doses of more than 400 mg/day, has docu- 
mented in vivo activity against most Candida and .4speqqillirs species. 
ac well as a wide array of other fungal pathogens. The new 
cyclodextriii-based oral solution and intravenous preparation show 
improved absorption, but compliance appears to be limited. Trans- 
plant recipients on cyclosporin require an immediate dose reduction 
followed by frequent monitoring. Starting treatment with intra- 
venous amphotericin B followed by oral itraconazole appears to be a 
feasible and effective approach. Voriconazole is a new, oral and 
intravenous triazole derivative with a broad spectrum of antifungal 
activity, including Aspergillus. In guinea pigs, voriconazole was 
superior to itraconazole and amphotericin B against jim@tus. 
After oral administration in human volunteers, a t,,,,, of less than 2 h 
and a f2 of 6 h have been observed. In non-neutropenic patients with 
chronic aspergillosis, 50% of whom had failed therapy with 
itraconazole or amphotericin B, 11/19 (58%) patients responded 
favorably to voricoiiazole (200 mg PO b.i.d.). In acute invasive 
aspergillosis in neutropenic hosts, a 6 nig/kg q l2  h IV dose of 
voriconazole was given for 1 day, followed by 3 mg/kg q12 h IV until 
the patient could take 200 mg PO b.i.d. This study comprised 141 
cases ofwhom 102 were assessable; 17% showed a complete response, 
36% a partial response, 2O%I a stable disease and 27% a failure. A 
survival rate of 58% was encountered among bone marrow transplant 
recipients. Around 8% of patients experienced transient visual 
disturbances. 
Clinical microbiology: a pivotal interface in 
patient and health care management 
m] Pre-laboratory specimen management: the first 
interface 
H. <k i s s .  HyXieric Instirut, Heidelbey, Germany 
Spiraling costs in the healthcare environment have obliged many 
medical microbiology laboratories to focus on cost-saving with the 
consequences of downsizing, outsourcing and the creation of cen- 
tralized laboratory facilities far away from the patients. Many 
clinicians and administrators are unaware that this development 
increases the risk ofproducing clinically irrelevant data, which in turn 
will have a significant negative impact on patient outcome and cost- 
effective healthcare delivery However, these circumstances are also to 
be blamed on microbiologists who too often have focused exclusively 
on laboratory workflow and diagnostic procedures, while neglecting 
the significance of the pre-analytic steps, including specimen 
selection, collection and transport. This ‘garbage-in-garbage-out’ 
situation produces laboratory data which may lead not only to 
misdiagnosis, extended length of stay, or inappropriate therapy, but 
also to important cost factors. It is well known that, often, specimens 
of the least clinical value require the most laboratory resources. 
Nothing is more important to the effectiveness of a laboratory than 
a specimen that has been appropriately selected, collected, and 
transported. 
Improvements in the early steps of the ‘total niicrobiology testing 
process’ include the following: including specimen nianagement in 
the curricula of medical and nursing schools; opening the black box 
‘micro-lab’ and making analytic procedures comprehensible and 
understandable; demonstrating the significance of expeditious trans- 
portation from patient bed to the laboratory; improving specimen 
collection material and transport media to inaintain ypecinien 
integrity 
Efficient specimen processing and data 
generation 
W. Goessens. Erasrnns I.irriwrsity Mfdical Ceitter, Roftcrdom, 
The h d r c r l a n d s  
Ongoing changes I n  infectiou, disease pathogens, patient populations 
and presentations of infectious diseases have increased the need for 
the rapid and accurate assessment of microbiological data. The 
speeding-up of the analytic process in the clinical microbiology 
laboratory should be adapted at several levels in order to tignificantly 
affect patient care. First. the analytic processes should be organized as 
efficiently as possible. Microbiological data are often obtained in a 
sequential order. This natural day-to-day rhythm can be changed by 
the introduction ofa change in working hours so that initial findings 
can be confirnied within one and the same working day instead of 
on the following day. Second, to be able to anticipate, relevant 
specimens and/or patient categories should bc monitored throughout 
the whole process ,of analysis. This can be achieved, for instance, by 
labeling of special patient categories, or by the analysis of their 
specimens by a dedicated technician, or by creating a special bench. 
Protocollation of analysis procedures and continuous education of 
technicians result In early recognition of significant pathogens or 
multiresistant organisms. The third level is to shorten the analysis 
process by applying new techniques or instruments. Replacing classic 
growth-based techniques by new and rapid instant techniques will 
not always automatically lead to a change in clinical decision-making. 
The correct impleinentation rather than the techniques themselves 
will be discussed. The speeding-up of the analytic process is only 
fruitful if the relevant information generated arrives earlier at the 
bedside of the pati,-nt without a delay of hours, or even days. This 
should be enabled by making use ofpresent information technologies 
by creating a laboratory information system which supports and 
facilitates laboratory workflow and ensures the reporting and/or 
summarizing of prdiminary or final results throughout the day. 
Sensing and responsiveness 
V Jarlier. Hopital P;fiC-SalpetriBre, Paris, France 
The laboratory of clinical microbiology plays a pivotal role in each 
medical institution by sensing the important medical and epideinio- 
logic events and developing feedback at patient and institution levels. 
The laboratory is a critical place to process and analyze the relevant 
microbiological data, and to integrate them with data from other 
sources in order to construct a vigilance system able to detect and 
report uncommon or abnormal events on the basis of quantitative or 
qualitative information. The laboratory should develop responses to 
patient and hospital context by (1) adapting workflows/techniques to 
new situations, (2) anticipating and performing additional investi- 
gations at paticnt or environmental lcvcls (e.g. search for MDK 
carriers among contact patients), ( 3 )  providing a basis ( e g  rpidemio- 
logic curve for MDR) for counseling, action and intervention. 
The prerequisites for meeting these priorities are both technical 
and managerial: the laboratory information system (LIS) should 
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provide patient files (1) containing relevant microbiological and non- 
microbiological (e.g. date of admission, time of surgery) information, 
thus requiring LIS/HIS connection, and (2) organized in a compre- 
hensive and workable manner (i.e. ready to use ‘at a glance’); the LIS 
should be able to generate qualitative/quantitative indicators for alert 
(e.g. readmission of an MDR carrier) and survey (e.g. list of patients 
with probable nosocomial infection), as well as workflows for inter- 
vention; a capability and willingness to communicate and interact 
should be encouraged by the institution through technician/MD 
training in basic epidemiology and case presentations in order to 
promote flexibility and responsiveness as an integral attribute of 
medical microbiology. 
Active involvement 
M. Tvede. Rigshospitalet, Copenhagen, Denmark 
Multiresistant bacteria are rarely seen in Danish hospitalized patients. 
Among other examples, MRSA occurred in only 0.5% in all tested 
strains in 1997, and vancomycin-resistant Enterococcns fecalis has only 
been described in two patients over the last 5 years. Additionally, 
aminoglycoside and quinolone resistances in E .  coli remain under 1% 
of the tested strains, with the penicillin resistance rate in pneumo- 
cocci only about 0.7%. These results should be considered in 
conjunction with the world’s lowest total usage of antibiotics, and 
with a low and controlled use of broad-spectrum antibiotics. These 
facts led us to identify the main reasons in our clinical microbiology 
daily practice and general organization which can explain this 
enjoyable situation. Improved intervention capabilities and effective 
communication with the different healthcare partners in the hospital 
enable the microbiologist to routinely act as a consultant and to 
actively contribute to critical healthcare management decisions. As a 
result, early diagnosis with appropriate antibiotic prescription is part 
of the normal routine in infectious diseases. Further efticiency is 
derived from successful development and implementation of 
antibiotic policy and laboratory networking. We would like to share 
our working experience and successes and propose useful recom- 
mendations which could reduce the spread of antibiotic resistance 
and prevent its predictable, negative consequences. 
The positive impact of clinical microbiology 
M.R. Gismondo. L. Sacco Teaching Hospital, Milan, Italy 
In the last 30 years we have seen great developments in the micro- 
biology laboratory, in both bacteriology and virology Bacterial 
isolation and identification and the related antibiotic susceptibility 
tests have become routine when the symptoms indicate the necessity. 
Thus, it is now possible to control the evolution ofinfectious diseases, 
the frequency of microbial isolation in various infections and anti- 
microbial resistance. However, today the healthcare system faces a 
rather peculiar situation with careful spending habits and an increas- 
ing unwillingness on the part of hospitals to invest in elements that 
cannot demonstrate immediate positive impact on patient care. 
Furthermore, the turnaround time for bacteriologic results does not 
always coincide with the amount of time needed to perform the test. 
This makes the optimization of not only pre-analytic and analytic 
stages of the test indispensable, but also the post-analytic stage. In 
parallel, it is very critical to demonstrate the usefulness of clinical 
microbiology in terms of both medical value for the patient and 
healthcare economic advantages. This can be achieved by compiling 
a clear and efficient report and by creating a close working relation- 
ship with the physicians. Formal and informal channels must be used 
to capture the attention of physicians, to demonstrate the correct use 
of antibiotics and to cooperate in preventing and limiting the spread 
of nosocomial infections. Formal cooperation ofmicrobiologists with 
hospital committees must complement this approach. The author 
will propose suggestions in order to obtain complete professional 
recognition ofthe clinical microbiologist from physicians, and to gain 
recognition of the economic advantages to be obtained in patient 
healthcare. 
Quality aspects in clinical microbiology 
wl Reporting strategies in clinical microbiology 
C. Block. Hadassah University Hospital, Clinical Microbiology and 
Infectious Diseases, ]emsalem, Israel 
The presentation of laboratory results to physicians has been the 
concern of laboratory directors since laboratories began. Clinical 
microbiology is a discipline so complex and constrained by techno- 
logical growth retardation that special demands and responsibilities 
are placed on laboratory directors to ensure accurate, relevant and 
dependable reporting. Providing detailed, comprehensive misleading 
reports is a frequent pitfall facing clinical microbiologists. Some 
investigators have proposed minimizing these flaws by utilizing 
strategies that impinge on the entire laboratory process, from receipt 
of specimens to design and delivery of reports. Simply put, a 
reporting strategy is a form of presenting laboratory test results 
designed to achieve a desired effect, e.g. to influence clinical practice. 
Strategies have been used for promoting prudent antibiotic use and 
have deployed integrative computer functions combining suscepti- 
bilities with biochemical, hematologic and radiologic data to assist 
infectious disease consultants or clinical pharmacists and alert them 
to problems. Reporting on underfilling of blood cultures is being 
evaluated as a measure for improving practice. Education of clinicians 
might include detailing rejection criteria for unacceptable specimens, 
communicating taxonomic changes, and adding reminders regarding 
notifiable dlseases and isolation alerts. Integral to a l l  the above is the 
obligation to ensure that the system works as it should. In some coun- 
tries regulation has forced the application of (sometimes extreme) 
quality assurance and validation procedures. Elsewhere, only the 
regulator’s compulsion is lacking. The professional and ethical obliga- 
tions of laboratory directors to ensure that the system delivers the 
goods are the same. 
Internal and external quality control for virus 
genome detection 
H. Zeichhardt’, H.-€? Grunert’, K.-0. Habermehl’. ‘Department of 
Virology, Institutefor Infections Diseases Medicine, University Hospital 
Benjamin Franklin, Free University of Berlin, Zlnstitutefor 
Biotechnological Diagnosticr, Berlin, Germany 
Objectives: Internal and external quality control have been directly 
interconnected in Germany since 1997 for improving and standard- 
izing the performance of virus genome detection by polymerase 
chain reaction and other nucleic acid amplification techniques. 
Methods: External quality assessment schemes (EQASs) for 
qualitative and quantitative genome detection of human immuno- 
deficiency virus 1 (HIV-l), hepatitis C virus (HCV) and hepatitis B 
virus (HBV) as well as qualitative detection of herpes viruses 
(cytomegalovirus, varizella zoster, and herpes simplex viruses types 1 
and 2) are performed twice a year by up to 180 laboratories. These 
EQASs are organized by the ’Institute for Standardization and 
